Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
Probl Endokrinol (Mosk) ; 68(2): 56-65, 2022 02 22.
Article Dans Russe | MEDLINE | ID: covidwho-2235942

Résumé

BACKGROUND: There is a lack of data on the features of dysglycemia in hospitalized patients with COVID-19 and concomitant diabetes mellitus (DM) confirmed by continuous glucose monitoring (CGM). AIM: to study the glycemic profile in hospitalized patients with COVID-19 and type 2 diabetes mellitus by continuous glucose monitoring and the role of steroid therapy in dysglycemiadevelopment. MATERIALS AND METHODS: We examined 21 patients with COVID-19 and DM 2 and 21 patients with DM 2 without COVID-19 (control group) using a professional 4-7-day CGM. We also compared two subgroups of patients with COVID-19 and DM 2: 1) patients received systemic glucocorticosteroids (GCS) during CGM and 2) patients in whomCGMwas performed after discontinuation of GCS. RESULTS: Compared with controls, patients with COVID-19 and DM2 had lesser values of glycemic «time in range¼ (32.7 ± 20.40 vs 48.0 ± 15.60%, p = 0.026) andhigher parameters of mean glycemia (p <0.05) but similar proportion of patients with episodes of hypoglycemia (33.3% vs 38.1%, p = 0.75). Patients who received dexamethasone during CGM were characterized by higher hyperglycemia and the absence of episodes of hypoglycemia. In patients who hadCGM after dexamethasone discontinuation, hyperglycemia was less pronounced, but 60% of them had episodes of hypoglycemia, often nocturnal, clinically significant and not detected by routine methods. CONCLUSION: Patients with COVID-19 and DM 2had severe and persistent hyperglycemia but a third of them hadalso episodes of hypoglycemia. During therapy with dexamethasone, they had the most pronounced hyperglycemia without episodes of hypoglycemia. In patients who underwent CGM after discontinuation of dexamethasone, hyperglycemia was less pronounced but 60% of them have episodes of hypoglycemia, often nocturnal, clinically significant and not diagnosed by routine methods. It would be advisable to recommend at least a 5-6-fold study of the blood glucose level (with its obligatory assessment at night) even for stable patients with COVID-19 and DM 2after the end of GCS treatment.


Sujets)
, COVID-19 , Diabète de type 2 , Hyperglycémie , Hypoglycémie , Glycémie , Autosurveillance glycémique , COVID-19/complications , Dexaméthasone/effets indésirables , Diabète de type 2/complications , Diabète de type 2/traitement médicamenteux , Humains , Hyperglycémie/traitement médicamenteux , Hypoglycémie/induit chimiquement , Stéroïdes
2.
Vestnik Tomskogo Gosudarstvennogo Universiteta-Pravo-Tomsk State University Journal of Law ; - (45):88-99, 2022.
Article Dans Russe | Web of Science | ID: covidwho-2100560

Résumé

"In connection with the ""covid"" restrictions and the need to carry out criminal proceedings in the conditions of distances and restrictions, the problem of digitalization of criminal proceedings is relevant, part of which being the transformation of the investigation and consideration of criminal cases into a digital format. The purpose of this article is to distinguish between the issues that need to be solved at the level of technical support for the transition of criminal cases from paper to digital format and issues that are legal to ensure such a transition at the legislative level and creation of legal norms in criminal procedural legislation for the possibility of using electronic criminal cases in criminal proceedings. To achieve this goal, the authors use the methods of analysis and synthesis, observation and description to study the current state of readiness of criminal proceedings and criminal procedural legislation for the transition to the use of electronic criminal cases, means, methods and methods of introducing electronic criminal cases into judicial practice, positive aspects and difficulties that will be associated with this. It is noted that in addition to the concept of ""criminal case"" the judicial practice uses the concept of ""materials of proceedings at the stage of execution of the sentence"" and ""materials of judicial proceedings on judicial control"" the digitalization of which is also necessary. Scientific definitions of the concept of ""criminal case"" are analyzed and its own definition is proposed. Attention is drawn to the need to form the concept of electronic criminal case in criminal procedure legislation. Moreover, the authors propose to develop a list of the main issues that require legislative regulation: to settle signing procedural documents with an electronic digital signature or certifying the conversion of a document from paper to digital format with the signature of an official. The procedure for familiarization with the electronic criminal case and electronic materials of the accused, convict, victim, who are in conditions of deprivation or restriction of liberty also needs to be enshrined in law. The authors propose to do this in specially equipped premises, on specially designed devices in places of deprivation or restriction of liberty. A procedure for familiarizing oneself with material (substantive) evidence at the request of the accused is proposed. To identify the problems of introducing the use of electronic criminal cases and materials, developing an algorithm for the actions of participants in criminal proceedings, it is proposed to do this gradually, and start with the materials of the proceedings on judicial control - when the court chooses a preventive measure or the use of other measures of procedural coercion, when the court authorizes the production of individual investigative actions, as well as when considering materials considered by the court at the stage of execution of sentence. This will make it possible to develop a stable algorithm of actions for professional participants in criminal proceedings, and will contribute to a faster and better introduction of modern technologies into criminal proceedings."

3.
Russian Journal of Cardiology ; 27(3):32-36, 2022.
Article Dans Russe | EMBASE | ID: covidwho-1870168

Résumé

Aim. To study the features of coronavirus disease 2019 (COVID-19) in patients with different severity of carbohydrate metabolism disorders (CMDs), taking into account the possible role of obesity in the acceleration of clinical and laboratory disorders. Material and methods. There were 137 consecutive patients admitted to the infectious disease hospital for COVID-19 patients. Three 3 groups were formed: Group 1 — 42 patients with concomitant type 2 diabetes (T2D);group 2 — 13 patients with concomitant prediabetes;group 3 — 82 patients without concomitant CMDs. Results. Patients with T2D tended to have a more severe disease course according to the SMRT-CO algorithm (p=0,089), which was associated with the longest hospital stay (p=0,038), the most pronounced (p=0,011) and prolonged (p=0,0001) decrease in oxygen saturation, the maximum percentage of lung injury at the beginning (p=0,094) and at the end (p=0,007) of hospitalization, the greater need for intensive care unit (p=0,050), as well as the highest increase in C-reactive protein and fibrinogen (hypercoagulability and systemic inflammation were noted in all groups). Patients with prediabetes in terms of COVID-19 severity occupied an intermediate position between those with T2D and without CMDs;at the same time, they most often needed the prescription of biological preparations (p=0,001). In the first and second groups, there were larger, compared with the control, proportions of obese people (61,9%, 53,8% and 30,5%, respectively, p=0,003). Prediabetes group had a strong correlation between the severity of viral pneumonitis according to SMRT-CO and the presence of obesity (R=0,69, p=0,009). Conclusion. In patients with impaired carbohydrate metabolism of any severity, COVID-19 is more severe. At the same time, persons with overt T2D are prone to the most severe COVID-19 course, while patients with prediabetes in terms of disease severity occupy an intermediate position between them and those without CMDs. Obesity is a strong risk factor for severe COVID-19 among patients with initial CMDs (prediabetes), which is partly mediated by prior liver dysfunction associated with the metabolic syndrome. The increase in proinflammatory changes and hypercoagulability is associated with COVID-19 severity in patients with and without CMDs. These disorders had the greatest severity and persistence in patients with T2D.

4.
Sovrem Tekhnologii Med ; 12(5): 6-16, 2021.
Article Dans Anglais | MEDLINE | ID: covidwho-1527051

Résumé

The aim of the investigation was to study the clinical course of COVID-19 in the presence of diabetes mellitus (DM) and elucidate possible mechanisms of their mutual aggravation. Materials and Methods: The study included 64 patients with COVID-19; of them, 32 were with DM (main group) and 32 were DM-free (control group). The groups were formed according to the "case-control" principle. During hospitalization, the dynamics of clinical, glycemic, and coagulation parameters, markers of systemic inflammation, as well as kidney and liver functions were monitored and compared. Results: Among patients with DM, the course of viral pneumonia was more severe, as evidenced by a 2.2-fold higher number of people with extensive (>50%) lung damage (p=0.05), an increased risk of death according to the CURB-65 algorithm (1.3-fold, p=0.043), and a longer duration of insufficient blood oxygen saturation (p=0.0004). With the combination of COVID-19 and DM, hyperglycemia is persistent, without pronounced variability (MAGE - 1.5±0.6 mmol/L), the levels of C-reactive protein (p=0.028), creatinine (p=0.035), and fibrinogen (p=0.013) are higher, manifestations of hypercoagulability persist longer, including slower normalization of antithrombin III (p=0.012), fibrinogen (p=0.037), and D-dimer (p=0.035). Conclusion: The course of COVID-19 in patients with DM is associated with a high severity and extension of pneumonia, persistent decrease in oxygen supply, high hyperglycemia, accelerated renal dysfunction, systemic inflammation, and hypercoagulability.


Sujets)
Troubles de l'hémostase et de la coagulation , COVID-19 , Diabète , Troubles de l'hémostase et de la coagulation/épidémiologie , Humains , Inflammation , SARS-CoV-2
SÉLECTION CITATIONS
Détails de la recherche